hydroxychloroquine has been researched along with regorafenib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amaravadi, RK; Brown, TJ; DiCicco, L; Garcia-Marcano, L; Karasic, TB; Massa, RC; Mitchell, TC; O'Dwyer, PJ; O'Hara, MH; Reiss, KA; Schneider, C; Teitelbaum, UR | 1 |
| Arora, SP; Curiel, T; Liu, Q; Mahalingam, D; Mendez, JA; Michalek, J; Morris, J; Sarantopoulos, J; Tenner, L | 1 |
2 trial(s) available for hydroxychloroquine and regorafenib
| Article | Year |
|---|---|
Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Colorectal Neoplasms; Humans; Hydroxychloroquine; Phenylurea Compounds; Pyridines; Weight Loss | 2022 |
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Colorectal Neoplasms; Humans; Hydroxychloroquine; Middle Aged; Phenylurea Compounds; Prospective Studies; Pyridines; Vorinostat | 2022 |